Tissue repair FDA Approved (Compounding)

Glutathione

A tripeptide antioxidant composed of glutamate, cysteine, and glycine, central to cellular detoxification, immune function, and oxidative stress defense.

AntioxidantDetoxImmuneSkin

Also referenced as: GSH, L-Glutathione, Reduced Glutathione

Also appears in: Longevity

Vial price compare
138 tracked offers across 138 vendors · 18 dosages
Best trust-adjusted value: Rocky Mountain Compounds · Strong trust · $0.02/mg
From
$0.02/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

-17.6% vs. Sep 6
Current low$0.02/mg
Market median$0.05/mg
Current coverage68 vendors
Observed window90 daily points
Lowest effective price Market median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Glutathione crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence 134 certificate records for Glutathione products, from 65 vendors 91 reference a report on the testing laboratory's own system · 73 have a laboratory lookup that answered when last checked · 121 match a vendor product page at the same address
Status
FDA Approved (Compounding)

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Tissue-repair research

Primary research area: Tissue repair. Also surfaces under Longevity for browsing and discovery.

Aliases
3

GSH, L-Glutathione, Reduced Glutathione

Signal depth
Medium

FDA label signal · 1548 trials · 198453 PubMed results

Early
Research evidence

Glutathione has human trials registered, but none have reported controlled results yet. Most current claims about what it does in people rest on preclinical (lab or animal) work, not published human data.

Glutathione has 6 name-matched clinical trials (1 international) (highest phase: Phase 1) and 198453 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

🌍 1 international trial
Human data
Phase 1
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
Top-tier journals
PHASE1 · Randomized The Effects of Obesity on Glutathione Levels in Patients With Chronic Periodontitis Before and After Periodontal Therapy PHASE1 Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels NA · Randomized Vitamin B-6 and Glutathione on Inflammation, Homocysteine, Oxidative Stress and Antioxidant Capacities ISRCTN A study on whether a natural sulforaphane supplement can boost glutathione levels Cellular Physiology and Biochemistry · 47,252 citations Short-Term Effects of Nose-Only Cigarette Smoke Exposure on Glutathione Redox Homeostasis, Cytochrome P450 1A1/2 and Respiratory Enzyme Activities in Mice Tissues Journal of Biological Chemistry · 18,243 citations Glutathione S-Transferases
Evidence history
  1. 2026-10-01 Promising → Early Band Promising → Early; -47 trials; +47 PubMed
  2. 2026-09-19 Early → Promising Band Early → Promising; +30 PubMed
  3. 2026-09-17 Promising → Early Band Promising → Early; -15 trials; +32 PubMed
  4. 2026-09-09 Early → Promising Band Early → Promising; +43 PubMed
  5. 2026-09-05 Promising → Early Band Promising → Early; -77 trials; +36 PubMed
  6. 2026-09-04 Early → Promising Band Early → Promising; +15 trials; +44 PubMed
  7. 2026-09-03 Promising → Early Band Promising → Early; +65 PubMed
  8. 2026-08-28 Early → Promising Band Early → Promising; -46 trials; +35 PubMed
  9. 2026-08-27 Promising → Early Band Promising → Early; +31 trials; +137 PubMed
  10. 2026-08-25 Early → Promising Band Early → Promising; +46 trials; +32 PubMed
  11. 2026-08-20 Promising → Early Band Promising → Early; -46 trials; +37 PubMed
  12. 2026-08-15 Early → Promising Band Early → Promising; +30 trials; +27 PubMed
  13. 2026-08-14 Promising → Early Band Promising → Early; +86 PubMed
  14. 2026-08-12 Early → Promising Band Early → Promising; +30 trials; +28 PubMed
  15. 2026-08-09 Promising → Early Band Promising → Early; -15 trials; +96 PubMed
  16. 2026-07-29 Early → Promising Band Early → Promising; +60 trials; +151 PubMed

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-03 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is glutathione?

Glutathione (GSH) is a tripeptide — gamma-glutamylcysteinylglycine — produced endogenously in every human cell. It is the body’s most abundant intracellular antioxidant and plays critical roles in Phase II detoxification, immune cell function, and redox signaling.

How it works

  • Direct antioxidant — GSH neutralizes reactive oxygen species (ROS) and reactive nitrogen species by donating electrons, becoming oxidized glutathione (GSSG) in the process (Forman et al., Archives of Biochemistry and Biophysics, 2009)
  • Conjugation reactions — glutathione S-transferases (GSTs) conjugate GSH to xenobiotics and endogenous toxins, facilitating their excretion (Hayes et al., Annual Review of Pharmacology and Toxicology, 2005)
  • Immune modulation — T-lymphocyte proliferation and natural killer cell activity depend on intracellular GSH levels (Dröge & Breitkreutz, Proceedings of the Nutrition Society, 2000)

Clinical use

Unlike most research peptides, glutathione has established medical applications:

  • Acetaminophen toxicity — IV N-acetylcysteine (a GSH precursor) is standard of care
  • Compounding pharmacies — injectable glutathione is available via prescription for off-label uses
  • Parkinson’s disease — IV glutathione has been studied as adjunctive therapy, though results are mixed (Mischley et al., Movement Disorders, 2017)
  • Skin lightening — widely used in aesthetic medicine; a systematic review found limited but suggestive evidence for melanin reduction (Weschawalit et al., Journal of Clinical and Aesthetic Dermatology, 2017)

Research status

Glutathione has extensive published literature (>170,000 PubMed entries). Key clinical references:

  • Richie et al. (2015) showed oral GSH supplementation increased body stores of glutathione in a randomized trial (European Journal of Nutrition, 54(2):251–263)
  • Allen & Bradley (2011) reviewed glutathione’s role in oxidative stress and aging (Age, 33(2):199–212)
  • Weschawalit et al. (2017) demonstrated skin-lightening effects of oral glutathione in a randomized, double-blind trial (Journal of Clinical and Aesthetic Dermatology, 10(10):14–17)

Key considerations

  • Available as IV, subcutaneous, oral, and sublingual formulations
  • Oral bioavailability is debated — liposomal and sublingual forms may improve absorption
  • Research vendor injectable formulations differ from pharmacy-compounded versions in quality oversight